Last reviewed · How we verify

Gabapentin + dexamethasone + ketamine

Glostrup University Hospital, Copenhagen · FDA-approved active Small molecule

This combination uses gabapentin to modulate neuropathic pain, dexamethasone to reduce inflammation, and ketamine to provide rapid-onset analgesia and anesthesia through NMDA receptor antagonism.

This combination uses gabapentin to modulate neuropathic pain, dexamethasone to reduce inflammation, and ketamine to provide rapid-onset analgesia and anesthesia through NMDA receptor antagonism. Used for Acute and chronic pain management in hospital/clinical settings, Procedural sedation and analgesia.

At a glance

Generic nameGabapentin + dexamethasone + ketamine
Also known asAnti-hyperalgesics, Postoperative pain
SponsorGlostrup University Hospital, Copenhagen
Drug classCombination therapy (anticonvulsant + corticosteroid + dissociative anesthetic)
TargetAlpha-2-delta calcium channel subunit (gabapentin); glucocorticoid receptor (dexamethasone); NMDA receptor (ketamine)
ModalitySmall molecule
Therapeutic areaPain management, Anesthesia
PhaseFDA-approved

Mechanism of action

Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing neurotransmitter release in neuropathic pain pathways. Dexamethasone is a corticosteroid that suppresses inflammatory responses. Ketamine acts as a non-competitive NMDA receptor antagonist, providing dissociative anesthesia and analgesia, particularly useful in acute pain management and procedural sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: